Datasets
Buyer room
INSIGHT-RX.COMManage supplier listing
InsightRX — Real-world observational pharmacokinetic dataset generated by bedside precision dosing: for every dosed patient episode, the patient characteristics and laboratory values used to individualise therapy, measured drug concentrations, the dose actually administered, the model's predicted exposure and recommended dose, and the resulting target attainment or adverse event. Two layers make this unusually valuable. First, it is field dosing data rather than trial data — dosing decisions and concentrations for real patients in real hospitals, including the special populations (renal impai…
supplier index read from their site
Real-world observational pharmacokinetic dataset generated by bedside precision dosing: for every dosed patient episode, the patient characteristics and laboratory values used to individualise therapy, measured drug concentrations, the dose actually administered, the model's predicted exposure and recommended dose, and the resulting target attainment or adverse event. Two layers make this unusually valuable. First, it is field dosing data rather than trial data — dosing decisions and concentrations for real patients in real hospitals, including the special populations (renal impairment, obesity, critical illness, paediatrics) that trials systematically exclude and that drug labels most often lack dosing guidance for. Second, a human-in-the-loop layer: each model dose recommendation carries the clinician's decision to accept or override it, and the platform's continuous-learning process uses accumulated outcomes to retrain the dosing models, so the corpus is already curated at model grade rather than raw.
From 10 yearsCoverage Health CareAsset class Equities
Sample, licence terms, pricing and eval results when InsightRX publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about InsightRX, answered from this page.
InsightRX — Real-world observational pharmacokinetic dataset generated by bedside precision dosing: for every dosed patient episode, the patient characteristics and laboratory values used to individualise therapy, measured drug concentrations, the dose actually administered, the model's predicted exposure and recommended dose, and the resulting target attainment or adverse event. Two layers make this unusually valuable. First, it is field dosing data rather than trial data — dosing decisions and concentrations for real patients in real hospitals, including the special populations (renal impai…
InsightRX offers (Alternative, Reference, Sentiment) — No vendor-stated totals. Structurally implies 1-20M dosing episodes across deployed institutions to date, each carrying a dense multi-point record — patient attributes, laboratory panel, measured concentrations, recommended and administered doses, and outcome — so roughly 20-150M discrete clinical observations. The scarcest component, and the one worth pricing, is measured drug-concentration-plus-dose tuples: an estimated 1-10M pairs, since these require therapeutic drug monitoring to have been ordered and represent the true pharmacokinetic ground truth. All figures inferred from institutional scale and dosing cadence, not published..
Pharmaceutical research and development: model-informed drug development and dose-optimisation support, exposure-response model refinement and external validation against field data, dosing guidance for special populations absent from trial cohorts — renally impaired, obese, critically ill, paediatric — and label supplementation evidence, an area regulators actively encourage. Clinical development: external control and simulation inputs, and dose-selection de-risking for compounds sharing a metabolic pathway. Machine learning: the clinician accept-versus-override pairs are expert preference supervision for building clinical decision-support models, and the exposure-dose-outcome tuples are training data for patient-simulation and digital-twin work; the plain-language query corpus supports natural-language-to-analytics models in a clinical register. Health-system operations: antimicrobial stewardship and medication-use benchmarking across institutions.
The data is with 10 years of history.
Coverage spans US; Biotechnology, Health Care Technology; alternative, reference, sentiment; equities.
InsightRX has not added their own details yet. Not yet on file: